Nichole Ann Reisdorph

US Patent:

20120128646, May 24, 2012

Filed:

Feb 16, 2010

Appl. No.:

13/147921

Inventors:

Kathryn Haskins - Denver CO, US
Thomas Delong - Denver CO, US
John W. Kappler - Denver CO, US
Brian Stadinski - N. Easton MA, US
Nichole Reisdorph - Centennial CO, US
Rick Reisdorph - Centennial CO, US

International Classification:

A61K 38/02
C07K 7/08
A61P 3/10
G01N 33/566
A61K 31/715
A61K 35/14
C07K 2/00
C12Q 1/02

US Classification:

424 9371, 530300, 530327, 435 29, 436501, 435 724, 435 71, 514 73, 514 54, 435 792

Abstract:

The present invention is related to the development and treatment of autoimmune disease. Autoimmune diseases can result from tissue damage caused by the activation of autoreactive T cells by autoantigens. For example, peptide fragments of naturally occurring proteins (i.e., for example, chromogranin A) may activate autoreactive T cells that result in the destruction of pancreatic β islet cells, possibly by the release of inflammatory cytokines (i.e., for example, interferon-γ). One naturally occurring biologically active chromogranin A peptide fragment, WE14, may comprise a diabetogenic autoantigen. Truncation and extension analysis of WE14 indicates that the stimulating binding register of WE14 occupies only half of the mouse IApeptide binding groove, leaving positions p1 to p4 empty. Inhibition of autoantigen-autoreactive T cell binding may provide therapeutic as well a prophylactic treatments for autoimmune diseases

US Patent:

20100112606, May 6, 2010

Filed:

Oct 19, 2009

Appl. No.:

12/581436

Inventors:

Michael Armstrong - Aurora CO, US
Nichole Ann-Marie Reisdorph - Centennial CO, US
Nathan Rabinovitch - Denver CO, US

International Classification:

G01N 33/542
C12Q 1/02
C12Q 1/26
H01J 49/26

US Classification:

435 792, 435 29, 435 25, 250282

Abstract:

The present invention provides a new analytical method for measuring leukotrienes in a clinical sample using liquid chromatography and tandem mass spectrometry (LCMSMS). The method provides a simple, rapid and low-cost assay for the measurement of leukotriene levels in a clinical sample with high accuracy and precision over the physiological range. The present invention further provides a method to determine the susceptibility of a subject to treatment with a leukotriene modifier, as wells as methods for diagnosis of a chronic obstructive disease of the airways and for predicting the risk of exacerbation of the same.